Eosinophilic Esophagitis: Towards Improved Management
EoStim
1 other identifier
observational
80
1 country
2
Brief Summary
The current project aims to improve the care for children and adolescents with eosinophilic esophagitis in a collaborative effort involving pediatric units at Oslo Unversity Hospital and Helse Bergen, Norway. Existing and new non-invasive biomarkers will be explored systematically, aiming to reduce the number of endoscopies and time on restricted diet.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2023
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 31, 2023
CompletedFirst Submitted
Initial submission to the registry
February 17, 2025
CompletedFirst Posted
Study publicly available on registry
May 28, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedMay 28, 2025
May 1, 2025
2.2 years
February 17, 2025
May 27, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Active eosinophilic esophagitis (>15 eosinophils per high-power field)
The eosinophil counts in a biopsy is used to classify active vs non-active eosinophilic esophagitis, and biomarkers are analysed using biopsy the gold standard to classify active vs inactive disease.
12 months
Interventions
Using biopsies as the gold standard, the project aims towards validating non-invasive biomarkers as specified previously against biopsies.
Eligibility Criteria
Children with newly diagnosed or previously confirmed eosinophilic esophagitis.
You may qualify if:
- a diagnosis of eosinophilic esophagitis
- suspected but not yet confirmed eosinophilic esophagitis
You may not qualify if:
- chronic severe conditions that preclude general anaestesia
- lack of consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Oslo University Hospitallead
- Helse-Bergen HFcollaborator
Study Sites (2)
Haukeland University Hospital
Bergen, Norway
OsloUH
Oslo, Norway
Biospecimen
Blood samples (EDTA), serum samples, oesophageal biopsies and brushes, stool samples.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ketil Størdal, PhD
University of Oslo
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 15 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
February 17, 2025
First Posted
May 28, 2025
Study Start
October 31, 2023
Primary Completion
December 31, 2025
Study Completion
December 31, 2025
Last Updated
May 28, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share
Not planned due to confidentiality